Vectibix
NDC Package 55513-955-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Vectibix is a medication used to treat a certain type of cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Marketed by Amgen Inc, this product is identified by NDC 55513-955 and is authorized under FDA application BLA125147.

Identification & Billing

NDC Package Code
55513-955-01
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE
Product Code
55513-955
11-Digit Billing Format
55513095501

Clinical Specifications

Proprietary Name
Vectibix
Dosage Form
-
Usage Information
This medication is used to treat a certain type of cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Panitumumab is a man-made protein (monoclonal antibody) that binds to a certain protein (epidermal growth factor receptor-EGFR). It works by slowing or stopping the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Amgen Inc
FDA Application #
BLA125147
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-10-2006
End Marketing Date
11-19-2018
Listing Expiration
11-19-2018
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55513-955-01 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 10 ml in 1 vial, single-dose of Vectibix, labeled by Amgen Inc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Amgen Inc on October 10, 2006. The current certification is valid through November 19, 2018.

What are the primary indications for this medication?

This medication is used to treat a certain type of cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Panitumumab is a man-made protein (monoclonal antibody) that binds to a certain protein (epidermal growth factor receptor-EGFR). It works by slowing or stopping the growth of cancer cells.

How is this Amgen Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55513095501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
55513-955-01
11-Digit CMS (5-4-2)
55513-0955-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.